Epigenetic therapy of cancer with 5-aza-2'-deoxycytidine (decitabine).

doi:10.1053/j.seminoncol.2005.07.008

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Epigenetic therapy of cancer with 5-aza-2'-deoxycytidine (decitabine).

Seminars in oncology - 1 Oct 2005

Momparler Richard L

Abstract excerpt

Epigenetic events, such as aberrant DNA methylation, have been demonstrated to silence the expression of many genes that suppress malignancy. Since the event is reversible, it is an interesting target for intervention with specific inhibitors of DNA methylation, such as 5-aza-2'-deoxycytidine (5-AZA-CdR, decitabine). 5-AZA-CdR is a prodrug that requires activation via phosphorylation by deoxcytidine kinase. The...

Topics

Alleles
Animals
Antimetabolites, Antineoplastic
Azacitidine
Cell Line, Tumor
Cellular Senescence
Clinical Trials as Topic
DNA
DNA Methylation
Decitabine
Disease Models, Animal
Dose-Response Relationship, Drug
Epigenesis, Genetic
Gene Silencing
Genes, Tumor Suppressor
Humans
Models, Biological
Models, Chemical

Source

Open in PubMed

Identifiers

PMID: 16210084
DOI: 10.1053/j.seminoncol.2005.07.008

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics